Drug combinations have become standard therapy for numerous diseases including malaria, HIV, tuberculosis, and cancers . Combination therapies can offer benefits such as enhanced efficacy, reduced toxicity, and avoiding the acquisition of monotherapy resistance . In the case of pancreatic cancer, the prognosis in the past ten years has remained unchanged , and treatments have become ineffective owing to growing resistance. Discovering antipancreatic cancer agents with high efficacy and low toxicity is crucial and constitutes one of the most challenging tasks for the scientific community working in oncology.